These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 18347402)

  • 21. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
    Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
    Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A case of advanced small cell lung cancer complicated by chronic renal failure treated with amrubicin].
    Isogai S; Totani Y; Kohashi Y; Mieno Y; Imizu H; Yoneda Y; Shimizu H; Hoshino T; Uchiyama Y; Takeuchi Y; Hayashi M; Saitoh Y; Sasaki F; Okazawa M; Sakakibara H
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1591-3. PubMed ID: 18799918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
    Yamamoto N; Sekine I; Nakagawa K; Takada M; Fukuoka M; Tanigawara Y; Saijo N
    Jpn J Clin Oncol; 2009 Jul; 39(7):425-30. PubMed ID: 19395467
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
    Han HS; Han JY; Yu SY; Pyo HR; Kim HY; Cho KH; Lee DH; Kim HT; Lee JS
    Cancer; 2008 Oct; 113(7):1623-31. PubMed ID: 18671241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
    Ghalaut PS; Sen R; Dixit G
    J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Profile of the anti-tumor effects of amrubicin, a completely synthetic anthracycline].
    Hanada M; Noguchi T; Murayama T
    Nihon Yakurigaku Zasshi; 2003 Aug; 122(2):141-50. PubMed ID: 12890900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of cisplatin-paclitaxel combination versus cisplatin-etoposide in patients with small-cell lung cancer: a Phase III study.
    Dimitroulis J; Rapti A; Stathopoulos GP; Rigatos S; Stathopoulos J; Koutantos J; Athanasiadis A; Tsikritsaki K; Karaindros D; Katis K; Antoniou D; Toumbis M; Giamboudakis P
    Oncol Rep; 2008 Oct; 20(4):879-84. PubMed ID: 18813830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.
    Makino Y; Makihara-Ando R; Ogawa T; Sato H; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Ohe Y; Yamamoto N
    Cancer Sci; 2019 Nov; 110(11):3573-3583. PubMed ID: 31505087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-related leucocytosis and chemotherapy-induced neutropenia: linked or independent prognostic factors for advanced non-small cell lung cancer?
    Maione P; Rossi A; Di Maio M; Gridelli C
    Lung Cancer; 2009 Oct; 66(1):8-14. PubMed ID: 19328587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amrubicin for the treatment of advanced lung cancer.
    Kurata T
    Expert Opin Drug Metab Toxicol; 2009 Feb; 5(2):171-80. PubMed ID: 19239396
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S; Nagato K; Kunii N; Yamamoto H; Yamasaki K; Okita K; Hanaoka H; Shimizu N; Suzuki M; Yoshino I; Taniguchi M; Fujisawa T; Nakayama T
    J Immunol; 2009 Feb; 182(4):2492-501. PubMed ID: 19201905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of amrubicin and its active metabolite amrubicinol in lung cancer patients.
    Matsunaga Y; Hamada A; Okamoto I; Sasaki J; Moriyama E; Kishi H; Matsumoto M; Hira A; Watanabe H; Saito H
    Ther Drug Monit; 2006 Feb; 28(1):76-82. PubMed ID: 16418698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Amrubicin].
    Shimizu T; Takada M; Yana T; Fukuoka M
    Nihon Rinsho; 2002 May; 60 Suppl 5():374-7. PubMed ID: 12101692
    [No Abstract]   [Full Text] [Related]  

  • 34. Thymic small cell carcinoma shows marked response to amrubicin.
    Igawa S; Murakami H; Yamamoto N
    J Thorac Oncol; 2009 Jun; 4(6):778. PubMed ID: 19461410
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.
    Kaira K; Sunaga N; Yanagitani N; Kawata T; Utsugi M; Shimizu K; Ebara T; Kawamura H; Nonaka T; Ishikawa H; Sakurai H; Suga T; Hara K; Hisada T; Ishizuka T; Nakano T; Mori M
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):109-14. PubMed ID: 18929446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small-cell lung cancer responds to amrubicin.
    Bosch X
    Lancet Oncol; 2007 Jan; 8(1):13. PubMed ID: 17354304
    [No Abstract]   [Full Text] [Related]  

  • 37. A dose-finding and pharmacokinetic study of nedaplatin in elderly patients with advanced non-small cell lung cancer.
    Yamamoto N; Tamura T; Kurata T; Yamamoto N; Sekine I; Kunitoh H; Ohe Y; Saijo N
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):79-88. PubMed ID: 19396598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Complete response of esophageal small cell carcinoma amrubicin treatment.
    Nagasaki E; Yuda M; Tanishima Y; Arakawa Y; Kobayashi K; Sakuyama T; Inoue D; Nishikawa K; Kobayashi M; Omura N; Kobayashi T; Aiba K
    J Infect Chemother; 2013 Aug; 19(4):770-5. PubMed ID: 23160626
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer.
    Socinski MA; Smit EF; Lorigan P; Konduri K; Reck M; Szczesna A; Blakely J; Serwatowski P; Karaseva NA; Ciuleanu T; Jassem J; Dediu M; Hong S; Visseren-Grul C; Hanauske AR; Obasaju CK; Guba SC; Thatcher N
    J Clin Oncol; 2009 Oct; 27(28):4787-92. PubMed ID: 19720897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction chemotherapy followed by concurrent chemoradiation for patients with non-operable stage III non-small-cell lung cancer.
    Iranzo V; Bremnes RM; Almendros P; Gavilá J; Blasco A; Sirera R; Camps C
    Lung Cancer; 2009 Jan; 63(1):63-7. PubMed ID: 18550204
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.